Retrospective analysis of real-world clinical use of comprehensive genomic profiling in solid tumors in Finland 2017-2020.

Background: Precision oncology has developed significantly during the last decade. To understand and describe the use of genomic profiling for cancer patients, we carried out a retrospective study in Finland. Materials and methods: The study included 297 patients who underwent comprehensive genomic profiling (CGP) as part of their clinical care during 2017-2020. In addition to the genomic data, relevant background and clinical information were gathered from the patient records. Additionally, the actionability of the test results, clinical response and survival were evaluated. Results: Most patients had either prostate (16.8%), breast (14.8%), or pancreatic cancer (11.8%). The majority of the patients had metastatic disease (85.8%) and had median age of 61 years. Patients were heavily pretreated, with 51.3% having received three or more treatment lines before CGP testing. Of the patients, 65.2% had at least one actionable alteration in their samples. The treatment decision was based on the CGP test result for 25.6% ( Conclusions: This study provides a descriptive analysis of the clinical and genomic characteristics of the Finnish CGP-cohort and explores the clinical outcomes. The results align with recent findings from other European countries and provide a context for ongoing prospective studies.